Journal: Investigational New Drugs

Article Title: Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma

doi: 10.1007/s10637-020-01040-y

Figure Lengend Snippet: Response of MPM and MeT-5A cell lines to fludarabine (F-araA) and risedronic acid (RIS) MPM- and MeT-5A cells (dotted red line) were treated with increasing concentrations (0.1 μM, 1 μM, 10 μM and 100 μM) of (A) F-araA and (B) RIS. Cell viability was measured after four days treatment using an ATP-based luminescence assay. Data represent mean ± SEM of three independent experiments, each performed in triplicate

Article Snippet: Gemcitabine was purchased from Chemodex, Fludarabine from AdooQ® Bioscience (Irvine, CA, USA), Risedronic Acid from LKT Laboratories (St Paul, MN USA), Cisplatin from AdipoGen® Life Science (Liestal, Switzerland).

Techniques: Luminescence Assay

Journal: Investigational New Drugs

Article Title: Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma

doi: 10.1007/s10637-020-01040-y

Figure Lengend Snippet: Proliferation of non-malignant line of mesotheliocytes, as LP-9 and HMC7, after treatment with fludarabine (F-araA) and risedronic acid (RIS) Proliferation rate was measured 24, 48 and 72 h after either vehicle (dotted lines) or drug treatment (this is day = 0), as F-araA at 1 μM (A, B) or RIS at 10 μM (C, D) . Data represent mean ± SEM of two independent experiments, each performed in duplicate

Article Snippet: Gemcitabine was purchased from Chemodex, Fludarabine from AdooQ® Bioscience (Irvine, CA, USA), Risedronic Acid from LKT Laboratories (St Paul, MN USA), Cisplatin from AdipoGen® Life Science (Liestal, Switzerland).

Techniques:

Journal: BMJ Open

Article Title: Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over­active bladder syndrome? An Australian cohort study

doi: 10.1136/bmjopen-2017-019027

Figure Lengend Snippet: PBS subsidy of drugs marketed for depression, osteoporosis and overactive bladder marketed by sponsoring companies

Article Snippet: Novartis, which markets zoledronic acid, and oestradiol/norethisterone, a hormone therapy approved for osteoporosis prevention in high-risk women intolerant of other products, sponsored 19.9% of events; Servier, which markets strontium, sponsored 15.0%; and Sanofi, which marketed risedronic acid until December 2014, sponsored 8.7%.

Techniques: